Cooperative Agreement U01CA308978
Award Date 4/1/26
Completion Date 3/31/31
Dollars Obligated $1.3M
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
Rochester, MN 55905, USA
Similar Awards
- Federal Cooperative Agreement Summary Mayo Clinic received a $266,736 Cooperative Agreement from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to validate a novel liquid biopsy assay for monitoring high-grade gliomas. The award, effective August 1, 2025 through July 31, 2026, supports technical and clinical validation of a circulating tumor DNA (ctDNA) plasma test that detects amplified genomic chromosomal junctions unique to individual...
- Federal Cooperative Agreement Summary Mayo Clinic Arizona received a $704,622 Cooperative Agreement from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) awarded August 15, 2025, with completion expected by May 31, 2027. The award supports preclinical studies focused on immunoprevention of multiple myeloma, specifically developing and utilizing immunocompetent mouse models (VKMYC and VKMYCHCRBN) that recapitulate the progression from smoldering multiple...
- Federal Cooperative Agreement Summary The National Cancer Institute (NCI) awarded a $941,798 Cooperative Agreement to the Beckman Research Institute of the City of Hope under the Cancer Biology Research program (CFDA 93.396) effective August 6, 2025, with completion scheduled for July 31, 2030. This research initiative focuses on elucidating the mechanisms by which RNA modification-mediated codon-biased translation supports acute myeloid leukemia (AML) development and therapeutic resistance. The...
- Federal Project Grant Award Summary Mayo Clinic Arizona has been awarded $420,000 in project grant funding from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), effective September 15, 2025, through August 31, 2027. The award funds a longitudinal research study examining quality of life (QOL) and patient priorities among older adults with indolent non-Hodgkin lymphoma (INHL). The study will leverage an existing lymphoma cohort and direct patient narratives to...
- Federal Cooperative Agreement Summary The National Cancer Institute (NCI) awarded Medstar Health Research Institute Inc. a Cooperative Agreement valued at $1,351,734 on July 25, 2025, under the Cancer Cause and Prevention Research program (CFDA 93.393) to deliver practical geriatric assessment services in community oncology settings. The primary objective is to increase the implementation and utilization of geriatric assessment protocols among older cancer patients (age 65+) in community-based...
- Federal Grant Award Summary Mayo Clinic received a $484,803 Project Grant award from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393), effective August 18, 2025, through July 31, 2030. This research initiative addresses the genetic basis of adult diffuse glioma by leveraging both germline and somatic genetic analyses to elucidate glioma risk and improve patient outcomes. The project builds upon genome-wide association studies (GWAS) that have...
- Cooperative Agreement Summary The National Cancer Institute (NCI) awarded a Cooperative Agreement valued at $2.56M to The University of Texas MD Anderson Cancer Center on August 22, 2025, under the Cancer Centers Support Grants program (CFDA 93.397). The award extends through July 31, 2030, and supports the Lymphoma Outcomes Specialized Program of Research Excellence (SPORE), which addresses significant disparities in lymphoma outcomes among African American and Hispanic patients. The center...
- Federal Cooperative Agreement Summary New York University School of Medicine is conducting a prospective biomarker discovery study funded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393). The cooperative agreement, valued at $703,423 and running from September 1, 2025 through August 31, 2030, supports research to identify circulating autoantibodies (AABs) associated with breast cancer risk using the NYU Women's Health Study cohort....
- The National Cancer Institute awarded St. Jude Children's Research Hospital Inc. a Cooperative Agreement under the Cancer Cause and Prevention Research program (CFDA 93.393) in the amount of $1,059,908, effective August 1, 2025, through July 31, 2030. This award supports continued longitudinal clinical assessment and follow-up services through the St. Jude Lifetime Cohort (SJLIFE) study, an established survivorship research resource that tracks long-term health outcomes in childhood cancer...
- Federal Cooperative Agreement Summary The National Cancer Institute (NCI) awarded a Cooperative Agreement valued at $639,882 to the University of North Carolina at Chapel Hill (UNC-CH), Office of Sponsored Research, effective August 1, 2025, through July 31, 2030, under the Cancer Biology Research program (CFDA 93.396). This award supports fundamental research into the molecular mechanisms underlying metastasis organ tropism—specifically, why certain breast cancer subtypes preferentially...